Low Dose Weekly Decitabine/Venetoclax
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 85 patients (estimated)
- Sponsors
- Montefiore Medical Center (Moses Campus)
- Tags
- BCL-2 Inhibitor, Hypomethylating Agents (HMA)
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1856
- NCT Identifier
- NCT05184842
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.